Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Is Meeting Merck Market Share Targets; Spin-Off Plan Moves Ahead

Executive Summary

Merck's market share within the Medco customer base is running about 33% higher than the company's overall national market share

You may also be interested in...



Medco/Merck Contract Gets New Spin; Renegotiation May Avert Zocor Impact

Medco's renegotiation of its rebate agreement with Merck may have allowed the pharmacy benefit manager to avoid loss of rebates accompanying Zocor'slooming patent expiration

Medco/Merck Contract Gets New Spin; Renegotiation May Avert Zocor Impact

Medco's renegotiation of its rebate agreement with Merck may have allowed the pharmacy benefit manager to avoid loss of rebates accompanying Zocor'slooming patent expiration

WellPoint/Anthem Merger Enhances Number Four PBM, Creates Big Buyer

WellPoint and Anthem see a "significant opportunity" to squeeze pharmaceutical prices as a result of the proposed merger between the two companies

Related Content

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel